Cargando…

Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells

OBJECTIVES: Interleukin (IL)-17 signalling has been shown to be a key regulator of disease in ankylosing spondylitis (AS) with several IL-17 blockers currently clinically approved. Despite this, the role of IL-17 in bone pathology is poorly understood. This study aimed to investigate IL-17 signallin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Mittal, Maroof, Asher, Gikas, Panos, Mittal, Gayatri, Keen, Richard, Baeten, Dominique, Shaw, Stevan, Roberts, Scott J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Spondyloarthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722278/ https://www.ncbi.nlm.nih.gov/pubmed/32723833 http://dx.doi.org/10.1136/rmdopen-2020-001306

Ejemplares similares

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
por: van der Heijde, Désirée, et al.
Publicado: (2020)

New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function
por: Saviano, Anella, et al.
Publicado: (2023)

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
por: Glatt, Sophie, et al.
Publicado: (2018)

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F
por: Adams, Ralph, et al.
Publicado: (2020)

Interleukin (IL)-12 and IL-18 Synergize to Promote MAIT Cell IL-17A and IL-17F Production Independently of IL-23 Signaling
por: Cole, Suzanne, et al.
Publicado: (2020)

MAIT cells: potent major cellular players in the IL-17 pathway of spondyloarthritis?
por: Toussirot, Eric, et al.
Publicado: (2018)

Evidence that tissue resident human enthesis γδT-cells can produce IL-17A independently of IL-23R transcript expression
por: Cuthbert, Richard James, et al.
Publicado: (2019)

Peptide-based vaccine targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats
por: Hayashi, Hiroki, et al.
Publicado: (2023)

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
por: van der Heijde, Désirée, et al.
Publicado: (2023)

First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis
por: Glatt, Sophie, et al.
Publicado: (2017)

Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial
por: Wei, James Cheng-Chung, et al.
Publicado: (2021)

Expansion of Interleukin‐22– and Granulocyte–Macrophage Colony‐Stimulating Factor–Expressing, but Not Interleukin‐17A–Expressing, Group 3 Innate Lymphoid Cells in the Inflamed Joints of Patients With Spondyloarthritis
por: Blijdorp, Iris C. J., et al.
Publicado: (2019)

Identification of myeloid cells in the human enthesis as the main source of local IL-23 production
por: Bridgewood, Charlie, et al.
Publicado: (2019)

Interleukin-17+CD8+ T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression
por: Menon, Bina, et al.
Publicado: (2014)

Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms
por: Tam, Hoi Ki Joshua, et al.
Publicado: (2022)

IL-17 in spondyloarthritis: is the T-party over?
por: Yeremenko, Nataliya, et al.
Publicado: (2011)

Trends in amyloidosis in spondyloarthritis: results from the Spanish National Inpatient Registry over a 17-year period (1999–2015)—TREND-EspA study
por: Mazzucchelli, Ramon, et al.
Publicado: (2021)

Trends in orthopaedic surgery for spondyloarthritis: outcomes from a National Hospitalised Patient Registry (MBDS) over a 17-year period (1999–2015).TREND-EspA study
por: Mazzucchelli, Ramón, et al.
Publicado: (2022)

Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis
por: de Winter, Janneke J, et al.
Publicado: (2019)

Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2
por: Van den Bosch, Filip, et al.
Publicado: (2018)

Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)
por: Deodhar, Atul A., et al.
Publicado: (2016)

Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort
por: Turina, Maureen C, et al.
Publicado: (2017)

IL-17A deficiency promotes periosteal bone formation in a model of inflammatory arthritis
por: Shaw, Anita T., et al.
Publicado: (2016)

IL17eScan: A Tool for the Identification of Peptides Inducing IL-17 Response
por: Gupta, Sudheer, et al.
Publicado: (2017)

Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system
por: How Shing Koy, Elsa, et al.
Publicado: (2021)

Magnetic Resonance Imaging of the Sacroiliac Joints Indicating Sacroiliitis According to the Assessment of SpondyloArthritis international Society Definition in Healthy Individuals, Runners, and Women With Postpartum Back Pain
por: de Winter, Janneke, et al.
Publicado: (2018)

Progression From Subclinical Inflammation to Overt Spondyloarthritis in First‐Degree Relatives of Patients in Association With HLA–B27: The Pre‐Spondyloarthritis Cohort
por: de Jong, Henriëtte M. Y., et al.
Publicado: (2022)

No evidence for a direct role of HLA-B27 in pathological bone formation in axial SpA
por: Neerinckx, Barbara, et al.
Publicado: (2017)

Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis
por: Robak, Ewa, et al.
Publicado: (2019)

Activation‐Induced Killer Cell Immunoglobulin‐like Receptor 3DL2 Binding to HLA–B27 Licenses Pathogenic T Cell Differentiation in Spondyloarthritis
por: Ridley, Anna, et al.
Publicado: (2016)

Evidence for a second ankylosing spondylitis-associated RUNX3 regulatory polymorphism
por: Vecellio, Matteo, et al.
Publicado: (2018)

IL-17-induced dimerization of IL-17RA drives the formation of the IL-17 signalosome to potentiate signaling
por: Goepfert, Arnaud, et al.
Publicado: (2022)

IL-17A, IL-17RC polymorphisms and IL17 plasma levels in Tunisian patients with rheumatoid arthritis
por: Dhaouadi, Tarak, et al.
Publicado: (2018)

The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
por: Brembilla, Nicolo Costantino, et al.
Publicado: (2018)

IL-17 and IL-17-producing cells in protection versus pathology
por: Mills, Kingston H. G.
Publicado: (2022)

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
por: Glatt, Sophie, et al.
Publicado: (2019)

Spinal Inflammation in the Absence of Sacroiliac Joint Inflammation on Magnetic Resonance Imaging in Patients With Active Nonradiographic Axial Spondyloarthritis
por: van der Heijde, Désirée, et al.
Publicado: (2014)

Comparative Genomic Profiling of Synovium Versus Skin Lesions in Psoriatic Arthritis
por: Belasco, Jennifer, et al.
Publicado: (2015)

Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis
por: Mease, Philip, et al.
Publicado: (2015)

A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_81h5tb2p3he691r4fqg118e3n8